Journal of Translational Medicine

OCT 23, 2026 · JOURNAL ARTICLE

RNA editing as an epitranscriptomic immune switch in tumor immunity and cancer immunotherapy

Journal of Translational Medicine

RNA editing is a dynamically regulated posttranscriptional mechanism that expands transcriptomic diversity and modulates cellular phenotypes. Accumulating evidence indicates that R

OCT 21, 2026 · JOURNAL ARTICLE

Genomic determinants of overall survival in early-stage non–small cell lung cancer: a large-scale clinical sequencing cohort analysis with independent cohort comparison

Journal of Translational Medicine

Despite curative-intent surgery, approximately 35% of patients with early-stage non–small cell lung cancer (NSCLC) die within five years. Identifying genomic determinants of surviv

OCT 21, 2026 · JOURNAL ARTICLE

Obesity and lymphoma: from pathobiology to clinical outcomes

Journal of Translational Medicine

Obesity is increasingly recognized as a systemic immunometabolic disorder that influences lymphoma risk, tumor biology, treatment response, and survivorship. Epidemiological eviden

OCT 20, 2026 · JOURNAL ARTICLE

ESR1 mutations in HR+/HER2− advanced breast cancer: ctDNA-guided detection and treatment sequencing

Journal of Translational Medicine

Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) breast cancer is the most common molecular subtype of advanced breast cancer (ABC). The comb

OCT 16, 2026 · JOURNAL ARTICLE

The companion diagnostic paradox of B7-H3/CD276-targeted therapy: why antigen expression is insufficient to predict ADC and cell therapy response

Journal of Translational Medicine

B7-H3, also known as CD276, is a transmembrane member of the B7 immune-regulatory family and has emerged as a therapeutically attractive pan-cancer target. Its broad expression acr

OCT 13, 2026 · JOURNAL ARTICLE

Phase-resolved lipid reprogramming in MASLD/MASH-associated hepatocellular carcinoma: pathogenesis, risk interception, and biomarker-matched therapeutic strategies

Journal of Translational Medicine

Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are increasingly important substrates for hepatocellula

OCT 9, 2026 · JOURNAL ARTICLE

RGS protein–orchestrated microenvironment remodeling in tumor immunity: from mechanism to therapy

Journal of Translational Medicine

Regulators of G protein signaling (RGS) proteins are G protein-coupled receptor (GPCR) signaling modulators defined by a conserved RGS domain that accelerates Gα-GTP hydrolysis to

OCT 5, 2026 · JOURNAL ARTICLE

CBP-mediated H3K18 lactylation drives GLI2 transcription to promote progression and EGFR-targeted therapy resistance in head and neck squamous cell carcinoma

Journal of Translational Medicine

Protein lactylation plays critical roles in cancer, but the participation of histone H3 lysine 18 lactylation (H3K18la) in the progression and EGFR-targeted therapy resistance in h